Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Assets: 2022-2024

Historic Other Non-Current Assets for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $2.0 million.

  • Centessa Pharmaceuticals' Other Non-Current Assets fell 28.78% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 28.78%. This contributed to the annual value of $2.0 million for FY2024, which is 19.89% down from last year.
  • As of FY2024, Centessa Pharmaceuticals' Other Non-Current Assets stood at $2.0 million, which was down 19.89% from $2.6 million recorded in FY2023.
  • Centessa Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $2.6 million during FY2023, with a 5-year trough of $1.9 million in FY2022.
  • Moreover, its 3-year median value for Other Non-Current Assets was $2.0 million (2024), whereas its average is $2.2 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Other Non-Current Assets skyrocketed by 35.85% in 2023, and later fell by 19.89% in 2024.
  • Centessa Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $1.9 million in 2022, then skyrocketed by 35.85% to $2.6 million in 2023, then decreased by 19.89% to $2.0 million in 2024.